Retatrutide | GLP1 Alpha
← All categoriesLilly's investigational triple-receptor agonist.
-
Best Peptide to Stack With Retatrutide
The best peptide to stack with retatrutide is BPC-157 for gut and tissue support. Full stacking guide with receptor overlap, clearance, and safety rules.
-
Does Retatrutide Cause Diarrhea?
Yes. Retatrutide causes diarrhea in about 9% to 21% of users in Phase 2 trials, dose dependent. Why it happens, how long it lasts, how to manage it.
-
How Does Retatrutide Work?
How retatrutide works: a triple agonist that hits GLP-1, GIP, and glucagon receptors at once. Mechanism, pharmacology, half-life, and the trial data.
-
How to Get Retatrutide
How to get retatrutide in 2026: only clinical trials offer legal, supervised access. Research peptides exist in a gray market with no FDA oversight.
-
How to Inject Retatrutide
How to inject retatrutide: reconstitute, draw units on a U-100 insulin syringe, inject SC at 90 degrees into abdomen, thigh, or arm, rotate sites.
-
Retatrutide Clinical Trials
Retatrutide clinical trials: Phase 2 NEJM data (24.2% weight loss), Phase 2 T2D Lancet results, the Phase 3 TRIUMPH program, and FDA filing timeline.
-
Retatrutide Cost
Retatrutide cost in 2026: trial enrollment is free, no commercial price exists yet, gray-market peptide vials run $200 to $500 per month with no QA.
-
Retatrutide Dosage Chart
Retatrutide dosage chart from Phase 2: 2 mg start, double every 4 weeks to 12 mg weekly. Full mg-to-mL-to-units table for 5, 10, and 20 mg/mL vials.
-
Retatrutide Hair Loss
Retatrutide hair loss is telogen effluvium triggered by rapid weight loss, not direct follicle toxicity. Timeline, mechanisms, and a prevention protocol.
-
Retatrutide Reconstitution
Retatrutide reconstitution math, common BAC water protocols, insulin syringe units, storage, and the regulatory reality: it is not FDA approved.
-
Retatrutide Side Effects
Retatrutide side effects from Phase 2 trial data: GI symptoms dominate at highest doses, with nausea near 62%. Not FDA approved as of 2026.
-
Retatrutide Weight Loss: Trial Results, Doses, and Timeline
Retatrutide weight loss data: 24.2% at 12 mg in Phase 2, ~28.7% in TRIUMPH-4 Phase 3. Dose-by-dose results, timeline, and how to access it.
-
What Is Retatrutide?
Retatrutide is Eli Lilly's investigational triple agonist (GIP/GLP-1/glucagon) in Phase 3 trials, with up to ~24% weight loss in Phase 2 data.